MannKind Corp. Company Profile (NASDAQ:MNKD)

About MannKind Corp.

MannKind Corp. logoMannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: MNKD
  • CUSIP: 56400P20
Key Metrics:
  • Previous Close: $0.62
  • 50 Day Moving Average: $0.795
  • 200 Day Moving Average: $1.140
  • 52-Week Range: $0.55 - $3.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.21
  • P/E Growth: -0.090
  • Market Cap: $304.04M
  • Outstanding Shares: 478,048,000
  • Beta: 1.69
Profitability:
  • Return on Assets: -66.16%
Debt:
  • Debt-to-Equity Ratio: -0.40%
  • Current Ratio: 0.31%
  • Quick Ratio: 0.30%
Additional Links:
Companies Related to MannKind Corp.:

Analyst Ratings

Consensus Ratings for MannKind Corp. (NASDAQ:MNKD) (?)
Ratings Breakdown: 4 Sell Ratings, 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Hold (Score: 1.71)
Consensus Price Target: $2.79 (358.13% upside)

Analysts' Ratings History for MannKind Corp. (NASDAQ:MNKD)
Show:
DateFirmActionRatingPrice TargetDetails
8/31/2016S&P Equity ResearchLower Price Target$0.84 -> $0.70View Rating Details
8/21/2016Piper Jaffray Cos.Set Price TargetSell$0.10View Rating Details
8/8/2016JPMorgan Chase & Co.Reiterated RatingSellView Rating Details
6/1/2016Royal Bank Of CanadaLower Price TargetUnderperform$1.00 -> $0.15View Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldView Rating Details
4/1/2016Goldman Sachs Group Inc.Reiterated RatingSellView Rating Details
1/6/2016Griffin SecuritiesUpgradeNeutral -> Buy$4.00View Rating Details
11/14/2015Jefferies GroupReiterated RatingBuy$9.00View Rating Details
5/11/2015MLV & Co.Lower Price TargetHold$7.00 -> $4.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for MannKind Corp. (NASDAQ:MNKD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2016        
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)ViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.04($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.12)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for MannKind Corp. (NASDAQ:MNKD)
Current Year EPS Consensus Estimate: $-0.230 EPS
Next Year EPS Consensus Estimate: $-0.190 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.03)($0.03)($0.03)
Q2 20161($0.03)($0.03)($0.03)
Q3 20161($0.03)($0.03)($0.03)
Q4 20161($0.03)($0.03)($0.03)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for MannKind Corp. (NASDAQ:MNKD)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for MannKind Corp. (NASDAQ:MNKD)
Insider Ownership Percentage: 0.94%
Institutional Ownership Percentage: 18.90%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.00View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.00View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.00View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.12View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for MannKind Corp. (NASDAQ:MNKD)
DateHeadline
News IconTrading the Biotech News: MannKind Corp. (NASDAQ:MNKD), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar (NASDAQ:MNKD)
voiceregistrar.com - September 28 at 11:07 AM
investopedia.com logoCan MannKind Compete Against Mylan's EpiPen? (MNKD) - Investopedia (NASDAQ:MNKD)
www.investopedia.com - September 27 at 6:03 PM
News Icon2 Biotech Stocks News And Price Trends: MannKind Corp. (NASDAQ:MNKD), Northwest Biotherapeutics, Inc ... - The Voice Registrar (NASDAQ:MNKD)
voiceregistrar.com - September 27 at 6:03 PM
News IconTop Biotechnology Stock Picking: Gilead Sciences Inc. (GILD), MannKind Corp. (MNKD) - The Independent Republic (NASDAQ:MNKD)
theindependentrepublic.com - September 27 at 6:03 PM
News IconTop Biotechnology Stock Picking: Sarepta Therapeutics, Inc. (SRPT), MannKind Corp. (MNKD) - The Independent Republic (NASDAQ:MNKD)
theindependentrepublic.com - September 27 at 6:03 PM
investopedia.com logoCan MannKind Compete Against Mylan's EpiPen? (MNKD) (NASDAQ:MNKD)
www.investopedia.com - September 26 at 6:11 PM
News IconMannKind Corporation (NASDAQ:MNKD) Delisting A Real Concern - The Oracle Dispatch (NASDAQ:MNKD)
oracledispatch.com - September 25 at 5:32 PM
streetinsider.com logoMannKind (MNKD) Receives Notice of Delisting (NASDAQ:MNKD)
www.streetinsider.com - September 23 at 5:48 PM
seekingalpha.com logoMannKind's Delisting Notice: Key Takeaways (NASDAQ:MNKD)
seekingalpha.com - September 23 at 5:48 PM
News IconMannKind (MNKD) Stock: Falling Hard On Delisting Notice (NASDAQ:MNKD)
cnafinance.com - September 23 at 5:48 PM
News IconKeen Investors Find News on MannKind Corp. (NASDAQ:MNKD) - Duncan Research (NASDAQ:MNKD)
www.duncanindependent.com - September 23 at 10:53 AM
seekingalpha.com logoMannKind's Delisting Notice: Key Takeaways - Seeking Alpha (NASDAQ:MNKD)
seekingalpha.com - September 23 at 10:53 AM
News IconNews review of 2 biotech stocks: MannKind Corp. (NASDAQ:MNKD), Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) - The Voice Registrar (NASDAQ:MNKD)
voiceregistrar.com - September 23 at 10:53 AM
News IconNews review of 2 biotech stocks: MannKind (NASDAQ:MNKD), PTC Therapeutics (NASDAQ:PTCT) - The Voice Registrar (NASDAQ:MNKD)
voiceregistrar.com - September 22 at 5:55 PM
News IconUnder the Microscope, Zeroing in at MannKind Corp. (NASDAQ:MNKD) - Duncan Research (NASDAQ:MNKD)
www.duncanindependent.com - September 22 at 5:55 PM
biz.yahoo.com logoNotice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tra (NASDAQ:MNKD)
biz.yahoo.com - September 22 at 10:59 AM
4-traders.com logoMANNKIND CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) (NASDAQ:MNKD)
www.4-traders.com - September 22 at 10:59 AM
biz.yahoo.com logoMANNKIND CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Tra (NASDAQ:MNKD)
biz.yahoo.com - September 22 at 10:59 AM
News IconPenny Stock Investors Keen on Shares of MannKind Corp. (NASDAQ:MNKD) - Duncan Research (NASDAQ:MNKD)
www.duncanindependent.com - September 21 at 5:52 PM
News IconActive Biotech Stock News: MannKind Corp. (MNKD), Alexion Pharmaceuticals, Inc. (ALXN) - The Independent Republic (NASDAQ:MNKD)
theindependentrepublic.com - September 21 at 5:52 PM
News IconNews review of 2 biotech stocks: MannKind Corp. (NASDAQ:MNKD ... - The Voice Registrar (NASDAQ:MNKD)
voiceregistrar.com - September 21 at 5:52 PM
News IconCIALIS WITHOUT A DOCTORS PRESCRIPTION - Online Cialis No Prescription (NASDAQ:MNKD)
richseo.in - September 21 at 10:19 AM
News IconStock to Watch: MannKind Corp (MNKD), Amyris (AMRS) - Newburgh Press (NASDAQ:MNKD)
newburghpress.com - September 20 at 11:22 AM
News IconHot Biotech Stocks Recap: Celgene Corporation (NASDAQ:CELG ... - The Voice Registrar (NASDAQ:MNKD)
voiceregistrar.com - September 16 at 5:59 PM
News IconTwo Biotechnology Names Are Hot: MannKind Corp. (MNKD), Celgene Corporation (CELG) - The Independent Republic (NASDAQ:MNKD)
theindependentrepublic.com - September 16 at 8:59 AM
News IconHC Stocks to Path=! MannKind Corporation (MNKD), Zoetis Inc (NYSE:ZTS) - share market updates (press release) (NASDAQ:MNKD)
sharemarketupdates.com - September 16 at 8:59 AM
investopedia.com logoMNKD: How MannKind's Stock Price Fell 28% in 6 Months (NASDAQ:MNKD)
www.investopedia.com - September 15 at 4:12 PM
capitalcube.com logoMannKind Corp. :MNKD-US: Earnings Analysis: Q2, 2016 By the Numbers : September 14, 2016 (NASDAQ:MNKD)
www.capitalcube.com - September 14 at 6:17 PM
News IconNew Market Report: MannKind Corporation (MNKD) - Medical Equipment - Deals and Alliances Profile (NASDAQ:MNKD)
reports.pr-inside.com - September 13 at 11:01 AM
investopedia.com logoMannKind Stock: 3 Things to Watch (MNKD) (NASDAQ:MNKD)
www.investopedia.com - September 13 at 11:01 AM
News IconTop Biotechnology Stock Picking: MannKind Corp. (MNKD), Inovio Pharmaceuticals, Inc. (INO) - The Independent Republic (NASDAQ:MNKD)
theindependentrepublic.com - September 12 at 5:57 PM
istreetwire.com logoStocks Buzz: NetApp, Inc. (NTAP) MannKind Corp. (MNKD) Superior Energy Services, Inc. (SPN) - iStreetWire (NASDAQ:MNKD)
istreetwire.com - September 12 at 5:57 PM
fool.com logoWhy MannKind Corp. Stock Fell 19.1% in August - Motley Fool (NASDAQ:MNKD)
www.fool.com - September 9 at 5:55 PM
fool.com logoWhy MannKind Corp. Stock Fell 19.1% in August (NASDAQ:MNKD)
www.fool.com - September 9 at 12:07 PM
News IconMannKind Corporation (MNKD) Stock: It’s Not Dead Yet! (NASDAQ:MNKD)
cnafinance.com - September 9 at 10:53 AM
News IconMannKind Corporation (MNKD) Stock: It's Not Dead Yet! - CNA Finance (press release) (NASDAQ:MNKD)
cnafinance.com - September 8 at 5:58 PM
News IconNews review of 2 biotech stocks: Medivation, Inc. (NASDAQ:MDVN ... - The Voice Registrar (NASDAQ:MNKD)
voiceregistrar.com - September 8 at 10:01 AM
investorplace.com logoMannKind Corporation (MNKD) Working to Take on Mylan’s EpiPen (NASDAQ:MNKD)
investorplace.com - September 6 at 3:33 PM
bizjournals.com logoValencia company developing inhaler alternative to EpiPen (NASDAQ:MNKD)
www.bizjournals.com - September 6 at 10:54 AM
thecountrycaller.com logoMannKind Corporation (MNKD) Rumored to Seek Partners for EpiPen Development - TCC (NASDAQ:MNKD)
www.thecountrycaller.com - September 5 at 5:34 PM
thecountrycaller.com logoMannKind Corporation (MNKD) Rumored to Seek Partners for EpiPen Development (NASDAQ:MNKD)
www.thecountrycaller.com - September 5 at 10:29 AM
fool.com logo5 Red Flags on MannKind's Balance Sheet (NASDAQ:MNKD)
www.fool.com - September 4 at 3:30 PM
finance.yahoo.com logoMannKind Corporation to Present at the Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:MNKD)
finance.yahoo.com - September 2 at 6:10 PM
News IconBiotech news that matter for investors: MannKind Corp. (NASDAQ:MNKD), Array BioPharma Inc. (NASDAQ:ARRY) - The Voice Registrar (NASDAQ:MNKD)
voiceregistrar.com - September 2 at 11:01 AM
seekingalpha.com logoMannKind: EpiPen To The Rescue (NASDAQ:MNKD)
seekingalpha.com - September 1 at 6:04 PM
fool.com logoHere's Why MannKind Just Soared 15% (And Why You Shouldn't Buy the Hype) (NASDAQ:MNKD)
www.fool.com - September 1 at 2:16 AM
seekingalpha.com logoMannKind says EpiPen alternative is lead program; shares up 13% (NASDAQ:MNKD)
seekingalpha.com - August 31 at 12:38 PM
seekingalpha.com logoMannKind - Afrezza Scripts, Class Actions Suits, Nasdaq Listing, Insider Buys, Insurance Woes - What Investors Need To Keep In Mind (NASDAQ:MNKD)
seekingalpha.com - August 30 at 6:11 PM
feeds.benzinga.com logoMannKind Is 'Making Progress' On Its Alternative To Mylan's EpiPen, Report Says (NASDAQ:MNKD)
feeds.benzinga.com - August 30 at 5:40 PM
fool.com logoBetter Buy: Organovo Holdings, Inc. vs MannKind Corp. (NASDAQ:MNKD)
www.fool.com - August 30 at 5:00 PM

Social

MannKind Corp. (NASDAQ:MNKD) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff